Global blood cancer market size was valued at USD 57.23 billion in 2024 and is projected to reach USD 117.43 billion by 2032, with a CAGR of 9.40% during the forecast period of 2025 to 2032. The global business landscape is undergoing a transformation, with industries increasingly leaning on deep research and actionable insights to make strategic decisions. One segment seeing tremendous...

In the field of hematologic malignancies, every breakthrough in formulation and delivery technology represents the opening of a new door toward more convenient and safer treatment for patients. Darzalex Faspro® (generic name: daratumumab, subcutaneous injection), with its unique advantage as the world’s first, China’s first, and currently the only subcutaneous anti-CD38...